Nadolol (SQ-11725): Non-Selective Beta-Adrenergic Blocker for Cardiovascular Research

Executive Summary: Nadolol (SQ-11725) is a non-selective beta-adrenergic receptor antagonist that blocks both β1 and β2 receptors, reducing heart rate and myocardial contractility in preclinical models (APExBIO product page). It is an orally active substrate of organic anion transporting polypeptide 1A2 (OATP1A2), impacting drug disposition in the context of transporter biology (Sun et al., 2025). Nadolol’s solid form, chemical formula C17H27NO4, and molecular weight of 309.40 Da define its handling and experimental use. Its stability is maintained at -20°C, but prepared solutions should be used promptly due to potential degradation. APExBIO’s Nadolol (BA5097) is for research use only and has been used extensively in hypertension, angina, and vascular headache models (see comparison).

Biological Rationale

Nadolol (SQ-11725) is leveraged in cardiovascular research because it suppresses beta-adrenergic signaling, a pathway implicated in hypertension, angina pectoris, and vascular headaches (Sun et al., 2025). Beta-adrenergic receptors mediate sympathetic nervous system effects on heart rate, vascular tone, and myocardial oxygen demand. Non-selective blockers like Nadolol simultaneously inhibit both β1 (cardiac) and β2 (vascular/bronchial) receptors, distinguishing them from selective agents. OATP1A2, a key transporter in the absorption and disposition of drugs, recognizes Nadolol as a substrate. This property is relevant in studies of pharmacokinetic variability, particularly in disease models with altered transporter expression.

Mechanism of Action of Nadolol (SQ-11725)

Nadolol acts as a competitive antagonist at beta-adrenergic receptors. By occupying these sites, it blocks norepinephrine and epinephrine from activating the receptor. This antagonism leads to decreased heart rate (negative chronotropy) and reduced myocardial contractility (negative inotropy). The net effects are lower cardiac output and decreased oxygen demand, making the drug valuable for studying cardiovascular pathophysiology. As an OATP1A2 substrate, Nadolol’s cellular uptake is influenced by transporter expression and function. In preclinical models, OATP1A2 modulation alters Nadolol’s plasma and tissue distribution, affecting experimental outcomes (Sun et al., 2025). Nadolol’s non-selectivity means it also affects β2 receptors, influencing studies of vascular tone and bronchial reactivity.

Evidence & Benchmarks

• Nadolol reduces heart rate and systolic blood pressure in preclinical hypertension models by 15–25% at oral doses of 1–10 mg/kg, measured over 24 hours (Sun et al., 2025).
• As a substrate for OATP1A2, Nadolol's pharmacokinetics are altered in models with upregulated or downregulated transporter expression, affecting plasma levels by up to 40% in disease states (Sun et al., 2025).
• Storage at -20°C preserves Nadolol's chemical integrity (>98% purity) for up to 24 months; once in solution, stability decreases and use within 24 hours is recommended (APExBIO).
• In head-to-head cardiovascular disease models, Nadolol provides reproducible blockade of beta-adrenergic signaling, outperforming selective beta-blockers in dual receptor inhibition scenarios (Nadolol: Advancing Translational Cardiovascular Models).
• Shipping with Blue Ice maintains compound stability during transport for small molecules, as confirmed by lot testing (APExBIO).

Applications, Limits & Misconceptions

Nadolol (SQ-11725) has broad applications in cardiovascular research:

• Hypertension research: Validated as a model compound for studying beta-adrenergic signaling blockade (see optimized workflows). This article extends those workflows by integrating transporter biology and stability parameters.
• Angina pectoris studies: Used to probe myocardial oxygen demand and ischemia tolerance in animal models.
• Vascular headache research: Employed in protocols investigating neurovascular modulation.
• Cardiovascular disease models: Essential for benchmarking beta-adrenergic antagonism in translational experiments.

Common Pitfalls or Misconceptions

• Nadolol is not beta-1 selective: It blocks both β1 and β2 receptors; avoid using in protocols requiring selective β1 antagonism.
• Not for diagnostic or medical use: APExBIO’s Nadolol (SQ-11725) is for research purposes only (APExBIO).
• Instability in solution: Long-term storage in solution leads to degradation; always prepare fresh aliquots for each use.
• Pharmacokinetics can change in disease states: OATP1A2 expression or function can alter Nadolol distribution and clearance, affecting experimental reproducibility (Sun et al., 2025).
• Not effective for beta-adrenergic-independent pathways: Ineffective in models where signaling bypasses beta-adrenergic receptors.

Workflow Integration & Parameters

Nadolol (SQ-11725) (SKU BA5097) from APExBIO is a solid compound supplied at >98% purity. It is typically stored dry at -20°C. For in vitro studies, dissolve in aqueous buffer or DMSO and use within 24 hours to ensure compound integrity. In vivo, oral dosing of 1–10 mg/kg is standard for rodent models; dose and schedule should be optimized based on transporter status and endpoint. Shipping uses Blue Ice for small molecules, ensuring stability in transit. For cell-based assays, consider OATP1A2 expression, as it modulates Nadolol uptake and experimental outcomes (optimized cell-based protocols). This article clarifies transporter-linked variability and practical storage parameters, extending prior practical guidance.

Conclusion & Outlook

Nadolol (SQ-11725) remains a benchmark compound for cardiovascular research, particularly in hypertension, angina pectoris, and vascular headache models. Its non-selective receptor profile and OATP1A2 substrate status position it as an essential tool for translational studies, especially where transporter biology and pharmacokinetic variability are factors. By following validated storage and preparation protocols, researchers can maximize reproducibility and data integrity. For more information or to source Nadolol (SQ-11725), see the official APExBIO product page.